CB1 Receptor (D5N5C) Rabbit mAb #93815
- WB
- IP
Supporting Data
REACTIVITY | H M R |
SENSITIVITY | Endogenous |
MW (kDa) | 60 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
CB1 Receptor (D5N5C) Rabbit mAb recognizes endogenous levels of total CB1 Receptor protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domains of mouse CB1 Receptor protein.
Background
The endocannabinoid system consists of the cannabinoid receptors, CB1 and CB2 receptors, the enzymes that produce and degrade the endogenous cannabinoid ligands (such as FAAH, DAG lipases, and MAG lipase), and the endocannabinoid ligands derived from the metabolism of arachidonic acid, 2-arachidonoylglycerol (2-AG) and anandamide (1-3). CB1 receptor belongs to the superfamily of G protein-coupled receptors (GPCRs) and harbors a large N-terminal extracellular domain, seven transmembrane domains, and a C-terminal intracellular tail. CB1 receptor is coupled to the Gai/o subunit of the G protein which inhibits adenylyl cyclases and regulates calcium and potassium ion channels (4). CB1 receptor is one of the most abundant GPCRs in the central nervous system. It has been show to play critical roles in the wiring of the brain during development (5), in neuronal plasticity (6), analgesia, drug abuse and metabolic homeostasis (4). In addition, CB1 receptor has been shown to interact with other GPCRs, to give rise to novel pharmacological and signaling heteromers with implication in diseases (7,8).
- Devane, W.A. et al. (1992) Science 258, 1946-9.
- Hanus, L. et al. (2001) Proc Natl Acad Sci U S A 98, 3662-5.
- Rozenfeld, R. (2011) Traffic 12, 12-8.
- Mackie, K. (2006) Annu Rev Pharmacol Toxicol 46, 101-22.
- Harkany, T. et al. (2008) Curr Opin Neurobiol 18, 338-45.
- Mackie, K. (2008) Mol Cell Endocrinol 286, S60-5.
- Rozenfeld, R. et al. (2011) EMBO J 30, 2350-63.
- Rozenfeld, R. et al. (2012) PLoS One 7, e29239.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.